Aulin Gel 3% 50g
AULIN GEL 50 g 3%
Tendinitis and acute joint pain
Recommended as a painkiller gel for the treatment of painful symptoms caused by tendonitis and sprains caused by the osteoarticular apparatus.
Symptomatic relief of pain associated with sprains and acute traumatic tendinitis.
In cases of hypersensitivity to the active ingredient or to any of the excipients. Use in patients in which aspirin or other medicinal products inhibiting prostaglandin synthesis, induced allergic reactions such as rhinitis, urticaria or bronchospasm. Use on broken or denuded skin or in the presence of local infections. Simultaneous use with other topical creams. Use in children under the age of 12 years.
Adults: Apply 2 or 3 times a day as a thin layer of gel (usually 3 g, corresponding to a line 6-7 cm long) and massage the affected area until completely absorbed. Duration of treatment: 7 - 15 days. Children under the age of 12: The drug has not been researched in children. There is no certainty on the safety and effectiveness of the product's use in children, therefore it should not be administered to children.
It should not be applied to skin wounds or open injuries. The product must not come into contact with the eyes or mucous membranes; in the event of accidental contact, wash immediately with water. The product should never be swallowed. Wash hands after application. Do not cover the treated skin with a restricting bandage or tight or waterproof clothing. Do not use in children under 12 years of age. You can reduce the side effects by using the lowest possible dose for the shortest time possible. Apply with caution in patients with active gastrointestinal bleeding or suspected peptic ulcers, severe renal or hepatic dysfunction, severe coagulation disorders or severe heart failure / uncontrolled. Since it has not been studied in hypersensitive patients, particular caution should be exercised when treating patients with hypersensitivity to other NSAIDs. You can not exclude the possibility of hypersensitivity during treatment. Since a burning sensation and, in exceptional cases, photodermatitis may occur when applied alongside topical NSAIDs, particular care should be taken during treatment with the product. To reduce the risk of photosensitivity, patients should be cautious of exposure to direct sunlight or tanning lamps. If symptoms persist or the condition worsens, seek medical attention. The product contains parahydroxybenzoates: these substances can cause l the onset of allergic reactions, including delayed-type reactions. The medicine can cause a temporary yellow colouring of the treated area, as well as to the clothing that it comes in contact with.
There are no known or expected interactions between this product and other pharmaceutical products.
No data is available on topical use during pregnancy or lactation. Therefore, do not use the product during pregnancy or lactation, unless it is absolutely necessary to do so.